You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameImipramine
Accession NumberDB00458  (APRD00672, DB08002)
TypeSmall Molecule
GroupsApproved
DescriptionImipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as imipramine and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. Imipramine has less sedative and anticholinergic effects than the tertiary amine TCAs, amitriptyline and clomipramine. See toxicity section below for a complete listing of side effects. Imipramine may be used to treat depression and nocturnal enuresis in children. Unlabeled indications include chronic and neuropathic pain (including diabetic neuropathy), panic disorder, attention-deficit/hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD).
Structure
Thumb
Synonyms
10,11-dihydro-N,N-Dimethyl-5H-dibenz[b,F]azepine-5-propanamine
3-(5H-DIBENZO[b,F]azepin-5-yl)-N,N-dimethylpropan-1-amine
5-[3-(dimethylamino)Propyl]-10,11-dihydro-5H-dibenz[b,F]azepine
Antideprin
Imipramin
Imipramine
Imipraminum
Imizine
Irmin
Melipramine
N-(gamma-Dimethylaminopropyl)iminodibenzyl
N-(γ-dimethylaminopropyl)iminodibenzyl
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ImipramineTablet10 mgOralAa Pharma Inc1976-12-31Not applicableCanada
ImipramineTablet75 mgOralAa Pharma Inc1989-12-31Not applicableCanada
ImipramineTablet25 mgOralAa Pharma Inc1975-12-31Not applicableCanada
ImipramineTablet50 mgOralAa Pharma Inc1975-12-31Not applicableCanada
Imipramine 10tabTablet10 mgOralPro Doc Limitee1976-12-312010-07-13Canada
Imipramine 25tabTablet25 mgOralPro Doc Limitee1976-12-312010-07-13Canada
Imipramine 50 Tab 50mgTablet50 mgOralPro Doc Limitee1978-12-312010-07-13Canada
Imipramine Hydrochloride Tablets 25mgTablet25 mgOralD.C. Labs Limited1977-12-312003-07-11Canada
Imipramine Hydrochloride Tablets 50mgTablet50 mgOralD.C. Labs Limited1977-12-312003-07-11Canada
Imipramine PamoateCapsule150 mg/1OralMallinckrodt, Inc.2009-10-15Not applicableUs
Imipramine PamoateCapsule75 mg/1OralMallinckrodt, Inc.2009-10-15Not applicableUs
Imipramine PamoateCapsule75 mg/1OralSTAT Rx USA LLC2009-10-15Not applicableUs
Imipramine PamoateCapsule100 mg/1OralMallinckrodt, Inc.2009-10-15Not applicableUs
Imipramine PamoateCapsule125 mg/1OralMallinckrodt, Inc.2009-10-15Not applicableUs
Imipramine Tab 25mgTablet25 mgOralDuchesnay Inc1978-12-312003-07-18Canada
ImprilTablet50 mgOralValeant Canada Lp Valeant Canada S.E.C.1974-12-312014-07-30Canada
ImprilTablet10 mgOralValeant Canada Lp Valeant Canada S.E.C.1974-12-312014-07-30Canada
ImprilTablet75 mgOralValeant Canada Lp Valeant Canada S.E.C.1988-12-312014-07-30Canada
ImprilTablet25 mgOralValeant Canada Lp Valeant Canada S.E.C.1974-12-312014-07-30Canada
Novo-pramine Tab 10mgTablet10 mgOralNovopharm Limited1971-12-31Not applicableCanada
Novo-pramine Tab 25mgTablet25 mgOralNovopharm Limited1971-12-31Not applicableCanada
Novo-pramine Tab 50mgTablet50 mgOralNovopharm Limited1971-12-31Not applicableCanada
PMS Imipramine Tab 10mgTablet10 mgOralPharmascience Inc1988-12-31Not applicableCanada
PMS Imipramine Tab 25mgTablet25 mgOralPharmascience Inc1988-12-31Not applicableCanada
PMS Imipramine Tab 50mgTablet50 mgOralPharmascience Inc1988-12-31Not applicableCanada
Tofranil 10mgTablet10 mgOralNovartis Pharmaceuticals Canada Inc1960-12-312001-07-30Canada
Tofranil 25mgTablet25 mgOralNovartis Pharmaceuticals Canada Inc1959-12-312008-07-18Canada
Tofranil 50mgTablet50 mgOralNovartis Pharmaceuticals Canada Inc1962-12-312010-11-29Canada
Tofranil 75mgTablet75 mgOralNovartis Pharmaceuticals Canada Inc1974-12-312008-07-18Canada
Tofranil-PMCapsule75 mg/1OralMallinckrodt, Inc.2009-11-042016-06-30Us
Tofranil-PMCapsule100 mg/1OralMallinckrodt, Inc.2009-11-042016-06-30Us
Tofranil-PMCapsule125 mg/1OralMallinckrodt, Inc.2009-11-042016-06-30Us
Tofranil-PMCapsule150 mg/1OralMallinckrodt, Inc.2009-11-042016-06-30Us
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-imipramineTablet25 mgOralApotex IncNot applicableNot applicableCanada
Apo-imipramineTablet50 mgOralApotex IncNot applicableNot applicableCanada
Apo-imipramineTablet75 mgOralApotex IncNot applicableNot applicableCanada
Apo-imipramineTablet10 mgOralApotex IncNot applicableNot applicableCanada
Imipramine HydrochlorideTablet10 mg/1OralPar Pharmaceutical Inc.1983-10-21Not applicableUs
Imipramine HydrochlorideTablet, film coated50 mg/1OralPhysicians Total Care, Inc.1992-11-12Not applicableUs
Imipramine HydrochlorideTablet, film coated10 mg/1OralLupin Pharmaceuticals, Inc.2010-12-21Not applicableUs
Imipramine HydrochlorideTablet10 mg/1OralKAISER FOUNDATION HOSPITALS2012-05-31Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralMutual Pharmaceutical Company, Inc.1990-06-05Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralExcellium Pharmaceutical, Inc2012-11-01Not applicableUs
Imipramine HydrochlorideTablet50 mg/1OralGolden State Medical Supply, Inc.1999-08-27Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralLeading Pharma, Llc2016-04-07Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralREMEDYREPACK INC.2007-11-19Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralA S Medication Solutions Llc1990-06-05Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralRichmond Pharmaceuticals, Inc.1990-06-05Not applicableUs
Imipramine HydrochlorideTablet, film coated50 mg/1OralSandoz Inc1976-04-20Not applicableUs
Imipramine HydrochlorideTablet50 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1983-10-21Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralAv Kare, Inc.2015-12-09Not applicableUs
Imipramine HydrochlorideTablet25 mg/1OralPar Pharmaceutical Inc.1983-10-21Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralPd Rx Pharmaceuticals, Inc.1976-04-20Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralLupin Pharmaceuticals, Inc.2010-12-21Not applicableUs
Imipramine HydrochlorideTablet, film coated50 mg/1OralREMEDYREPACK INC.2016-09-16Not applicableUs
Imipramine HydrochlorideTablet, film coated50 mg/1OralMutual Pharmaceutical Company, Inc.1990-06-05Not applicableUs
Imipramine HydrochlorideTablet, film coated50 mg/1OralExcellium Pharmaceutical, Inc2012-11-01Not applicableUs
Imipramine HydrochlorideTablet, film coated50 mg/1Oralbryant ranch prepack1990-06-05Not applicableUs
Imipramine HydrochlorideTablet, film coated50 mg/1OralLeading Pharma, Llc2016-04-07Not applicableUs
Imipramine HydrochlorideTablet, film coated50 mg/1OralNorthwind Pharmaceuticals, LLC2015-03-06Not applicableUs
Imipramine HydrochlorideTablet, film coated50 mg/1OralAv Kare, Inc.2015-12-09Not applicableUs
Imipramine HydrochlorideTablet, film coated50 mg/1OralRichmond Pharmaceuticals, Inc.1990-06-05Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralREMEDYREPACK INC.2009-10-13Not applicableUs
Imipramine HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2011-09-202016-11-15Us
Imipramine HydrochlorideTablet50 mg/1OralPar Pharmaceutical Inc.1983-10-21Not applicableUs
Imipramine HydrochlorideTablet10 mg/1OralGolden State Medical Supply, Inc.1999-08-27Not applicableUs
Imipramine HydrochlorideTablet, film coated50 mg/1OralLupin Pharmaceuticals, Inc.2010-12-21Not applicableUs
Imipramine HydrochlorideTablet, film coated10 mg/1OralSandoz Inc1976-04-20Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralA S Medication Solutions1976-04-20Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralA S Medication Solutions Llc1990-06-05Not applicableUs
Imipramine HydrochlorideTablet10 mg/1OralCarilion Materials Management1983-10-21Not applicableUs
Imipramine HydrochlorideTablet, film coated50 mg/1OralREMEDYREPACK INC.2013-07-08Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1Oralbryant ranch prepack2010-12-21Not applicableUs
Imipramine HydrochlorideTablet25 mg/1OralREMEDYREPACK INC.2011-09-212016-11-11Us
Imipramine HydrochlorideTablet, film coated25 mg/1OralREMEDYREPACK INC.2016-11-17Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralPhysicians Total Care, Inc.1993-02-02Not applicableUs
Imipramine HydrochlorideTablet, film coated10 mg/1OralLeading Pharma, Llc2016-04-07Not applicableUs
Imipramine HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2012-07-12Not applicableUs
Imipramine HydrochlorideTablet25 mg/1OralA S Medication Solutions Llc1983-10-21Not applicableUs
Imipramine HydrochlorideTablet25 mg/1OralGolden State Medical Supply, Inc.1999-08-27Not applicableUs
Imipramine HydrochlorideTablet, film coated10 mg/1OralRichmond Pharmaceuticals, Inc.1990-06-05Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralSandoz Inc1976-04-20Not applicableUs
Imipramine HydrochlorideTablet, film coated10 mg/1OralAv Kare, Inc.2015-12-09Not applicableUs
Imipramine HydrochlorideTablet, film coated10 mg/1OralMutual Pharmaceutical Company, Inc.1990-06-05Not applicableUs
Imipramine HydrochlorideTablet, film coated10 mg/1OralExcellium Pharmaceutical, Inc2012-11-01Not applicableUs
Imipramine PamoateCapsule100 mg/1OralLupin Pharmaceuticals, Inc.2010-04-16Not applicableUs
Imipramine PamoateCapsule125 mg/1OralWest Ward Pharmaceuticals Corp.2010-04-19Not applicableUs
Imipramine PamoateCapsule150 mg/1OralLUPIN LIMITED2010-04-16Not applicableUs
Imipramine PamoateCapsule125 mg/1OralLupin Pharmaceuticals, Inc.2010-04-16Not applicableUs
Imipramine PamoateCapsule150 mg/1OralWest Ward Pharmaceuticals Corp.2010-04-19Not applicableUs
Imipramine PamoateCapsule75 mg/1OralLUPIN LIMITED2010-04-16Not applicableUs
Imipramine PamoateCapsule150 mg/1OralLupin Pharmaceuticals, Inc.2010-04-16Not applicableUs
Imipramine PamoateCapsule75 mg/1OralWest Ward Pharmaceuticals Corp.2010-04-19Not applicableUs
Imipramine PamoateCapsule100 mg/1OralLUPIN LIMITED2010-04-16Not applicableUs
Imipramine PamoateCapsule75 mg/1OralLupin Pharmaceuticals, Inc.2010-04-16Not applicableUs
Imipramine PamoateCapsule125 mg/1OralLUPIN LIMITED2010-04-16Not applicableUs
Imipramine PamoateCapsule100 mg/1OralWest Ward Pharmaceuticals Corp.2010-04-19Not applicableUs
TofranilTablet, sugar coated10 mg/1OralMallinckrodt, Inc.2011-01-24Not applicableUs
TofranilTablet, sugar coated25 mg/1OralMallinckrodt, Inc.2011-01-24Not applicableUs
TofranilTablet, sugar coated50 mg/1OralMallinckrodt, Inc.2011-01-24Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AntidepTorrent
DepsonilAbbott
Depsonil-PMAbbott
ElaminBaroda
FronilJohnson
ImidolTanabe Mitsubishi Pharma
Imipramin DakNycomed
ImiprexDumex
PraminIncepta
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Imipramine Hydrochloride
113-52-0
Thumb
  • InChI Key: XZZXIYZZBJDEEP-UHFFFAOYSA-N
  • Monoisotopic Mass: 316.170626517
  • Average Mass: 316.868
DBSALT000099
Imipramine Pamoate
10075-24-8
Thumb
  • InChI Key: SBDXQUVAAJKLDH-UHFFFAOYSA-N
  • Monoisotopic Mass: 668.288637022
  • Average Mass: 668.7768
DBSALT000100
Categories
UNIIOGG85SX4E4
CAS number50-49-7
WeightAverage: 280.4073
Monoisotopic: 280.193948778
Chemical FormulaC19H24N2
InChI KeyBCGWQEUPMDMJNV-UHFFFAOYSA-N
InChI
InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3
IUPAC Name
(3-{2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)dimethylamine
SMILES
CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
Pharmacology
IndicationFor the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older. May also be used to manage panic disorders, with or without agoraphobia, as a second line agent in ADHD, management of eating disorders, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, and for symptomatic treatment of postherpetic neuralgia.
Structured Indications
PharmacodynamicsImipramine is a tricyclic antidepressant with general pharmacological properties similar to those of structurally related tricyclic antidepressant drugs such as amitriptyline and doxepin. A tertiary amine, imipramine inhibits the reuptake of serotonin more so than most secondary amine tricyclics, meaning that it blocks the reuptake of neurotransmitters serotonin and noradrenaline almost equally. With chronic use, imipramine also down-regulates cerebral cortical β-adrenergic receptors and sensitizes post-synaptic sertonergic receptors, which also contributes to increased serotonergic transmission. It takes approximately 2 - 4 weeks for antidepressants effects to occur. The onset of action may be longer, up to 8 weeks, in some individuals. It is also effective in migraine prophylaxis, but not in abortion of acute migraine attack.
Mechanism of actionImipramine works by inhibiting the neuronal reuptake of the neurotransmitters norepinephrine and serotonin. It binds the sodium-dependent serotonin transporter and sodium-dependent norepinephrine transporter preventing or reducing the reuptake of norepinephrine and serotonin by nerve cells. Depression has been linked to a lack of stimulation of the post-synaptic neuron by norepinephrine and serotonin. Slowing the reuptake of these neurotransmitters increases their concentration in the synaptic cleft, which is thought to contribute to relieving symptoms of depression. In addition to acutely inhibiting neurotransmitter re-uptake, imipramine causes down-regulation of cerebral cortical beta-adrenergic receptors and sensitization of post-synaptic serotonergic receptors with chronic use. This leads to enhanced serotonergic transmission.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent noradrenaline transporterProteinyes
inhibitor
HumanP23975 details
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
5-hydroxytryptamine receptor 2AProteinunknown
antagonist
HumanP28223 details
Histamine H1 receptorProteinno
antagonist
HumanP35367 details
Alpha-1A adrenergic receptorProteinno
antagonist
HumanP35348 details
Alpha-1D adrenergic receptorProteinno
antagonist
HumanP25100 details
Muscarinic acetylcholine receptor M1Proteinno
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinno
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinno
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinno
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinno
antagonist
HumanP08912 details
Potassium voltage-gated channel subfamily D member 2Proteinno
inhibitor
HumanQ9NZV8 details
Potassium voltage-gated channel subfamily D member 3Proteinno
inhibitor
HumanQ9UK17 details
5-hydroxytryptamine receptor 2CProteinunknown
antagonist
binder
HumanP28335 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
5-hydroxytryptamine receptor 7Proteinunknown
antagonist
HumanP34969 details
D(1) dopamine receptorProtein groupunknown
binder
Humannot applicabledetails
D(2) dopamine receptorProteinunknown
binder
HumanP14416 details
Potassium voltage-gated channel subfamily H member 2Proteinunknown
inhibitor
HumanQ12809 details
Sodium-dependent dopamine transporterProteinunknownNot AvailableHumanQ01959 details
5-hydroxytryptamine receptor 1AProteinunknown
activator
HumanP08908 details
5-hydroxytryptamine receptor 6Proteinunknown
binder
HumanP50406 details
Related Articles
AbsorptionRapidly and well absorbed after oral administration. Bioavailability is approximately 43%. Peak plasma concentrations usually attained 1 - 2 hours following oral administration. Absorption is unaffected by food.
Volume of distributionNot Available
Protein binding60-95%
Metabolism

Exclusively metabolized by the liver. Imipramine is converted in the liver by various CYP isoenzymes (e.g. CYP1A2, CYP2D6, CYP3A4, CYP2C9) to active metabolites desipramine and 2-hydroxydesipramine.

SubstrateEnzymesProduct
Imipramine
2-hydroxyimipramineDetails
Imipramine
DesipramineDetails
2-hydroxyimipramine
Not Available
2-hydroxy-imipramine glucuronideDetails
Route of eliminationApproximately 40% of an orally administered dose is eliminated in urine within 24 hours, 70% in 72 hours. Small amounts are eliminated in feces via the biliary elimination.
Half lifeImipramine - 8-20 hours; Desipramine (active metabolite) - up to 125 hours
ClearanceNot Available
ToxicityOral, rat LD50: 355 to 682 mg/kg. Toxic signs proceed progressively from depression, irregular respiration and ataxia to convulsions and death. Antagonism of the histamine H1 and α1 receptors can lead to sedation and hypotension. Antimuscarinic and anticholinergic side effects such as blurred vision, dry mouth, constipation and urine retention may occur. Cardiotoxicity may occur with high doses of imipramine. Cardiovascular side effects in postural hypotension, tachycardia, hypertension, ECG changes and congestive heart failure. Psychotoxic effects include impaired memory and delirium. Induction of hypomanic or manic episodes may occur in patients with a history of bipolar disorder. Withdrawal symptoms include GI disturbances (e.g. nausea, vomiting, abdominal pain, diarrhea), anxiety, insomnia, nervousness, headache and malaise.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Imipramine Metabolism PathwayDrug metabolismSMP00625
Imipramine Action PathwayDrug actionSMP00422
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4A AllelePoor drug metabolizer, lower dose requirements, higher risk for adverse side effects18070221
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4C > TThose that are homozygous for the poorly metabolizing CYP2D6 alleles are at an increased risk of side effects and decrease drug metabolism18070221
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4C > TThose that are homozygous for the poorly metabolizing CYP2D6 alleles are at an increased risk of side effects and decrease drug metabolism9918137
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Imipramine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
1,10-PhenanthrolineThe serum concentration of Imipramine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineImipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Imipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineImipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineImipramine may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Imipramine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
4-Bromo-2,5-dimethoxyamphetamineImipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineImipramine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Imipramine.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Imipramine.Experimental
AbirateroneThe serum concentration of Imipramine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Imipramine.Approved
AcenocoumarolImipramine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Imipramine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Imipramine.Approved
AcetaminophenThe serum concentration of Imipramine can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Imipramine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Imipramine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Imipramine.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Imipramine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Imipramine.Approved
AgmatineImipramine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Imipramine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Imipramine.Approved
AlbendazoleThe serum concentration of Imipramine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Imipramine.Approved
AldosteroneThe serum concentration of Imipramine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Imipramine can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Imipramine.Vet Approved
AlfentanilThe serum concentration of Imipramine can be increased when it is combined with Alfentanil.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Imipramine.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Imipramine.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Imipramine is combined with Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Imipramine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Imipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Imipramine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Imipramine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Imipramine.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Imipramine.Approved
AmantadineThe serum concentration of Imipramine can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Imipramine.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Imipramine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Imipramine.Approved
Aminohippuric acidThe serum concentration of Imipramine can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Imipramine.Approved, Withdrawn
AmiodaroneThe metabolism of Imipramine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Imipramine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Imipramine.Approved
AmlodipineThe serum concentration of Imipramine can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe metabolism of Imipramine can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Imipramine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Imipramine.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Imipramine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Imipramine.Approved, Investigational
AmprenavirThe serum concentration of Imipramine can be increased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Imipramine can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Imipramine.Approved
AnagrelideImipramine may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Imipramine.Approved
Antithrombin III humanThe serum concentration of Imipramine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Imipramine can be increased when it is combined with Apixaban.Approved
ApomorphineImipramine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineImipramine may decrease the antihypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Imipramine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Imipramine.Approved
AprotininThe serum concentration of Imipramine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Arbutamine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Imipramine.Approved, Investigational
ArgatrobanThe serum concentration of Imipramine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Imipramine.Approved, Investigational
ArmodafinilThe metabolism of Imipramine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Imipramine.Approved
Arsenic trioxideImipramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherImipramine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Imipramine.Approved
AsenapineImipramine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Imipramine can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Imipramine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Imipramine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Imipramine can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Imipramine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Imipramine can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Imipramine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Imipramine.Vet Approved
AzelastineImipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe serum concentration of Imipramine can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Imipramine.Approved
AzithromycinImipramine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Imipramine.Approved
BambuterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Bambuterol.Approved
BarbexacloneThe metabolism of Imipramine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Imipramine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Imipramine.Approved
BatimastatThe serum concentration of Imipramine can be increased when it is combined with Batimastat.Experimental
BedaquilineImipramine may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe serum concentration of Imipramine can be increased when it is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Imipramine.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Imipramine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Imipramine is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Imipramine can be increased when it is combined with Benzamidine.Experimental
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Imipramine.Approved
BenzocaineThe serum concentration of Imipramine can be increased when it is combined with Benzocaine.Approved
BenzphetamineImipramine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Imipramine.Approved
BepridilThe serum concentration of Imipramine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Imipramine.Approved, Vet Approved
BetaxololThe metabolism of Imipramine can be decreased when combined with Betaxolol.Approved
BethanidineImipramine may decrease the antihypertensive activities of Bethanidine.Approved
BexaroteneThe serum concentration of Imipramine can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Imipramine can be increased when it is combined with Bi201335.Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Imipramine is combined with Bifeprunox.Investigational
BiperidenThe serum concentration of Imipramine can be increased when it is combined with Biperiden.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Imipramine.Approved
BivalirudinThe serum concentration of Imipramine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Imipramine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Imipramine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Imipramine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Imipramine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Imipramine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Imipramine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Imipramine.Approved
BrimonidineImipramine may decrease the antihypertensive activities of Brimonidine.Approved
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Imipramine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Imipramine.Approved, Illicit
BromocriptineImipramine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Imipramine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Imipramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Imipramine.Approved, Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Imipramine.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Imipramine.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Imipramine.Approved, Investigational
BuprenorphineImipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Imipramine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Imipramine is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Imipramine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Imipramine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Imipramine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Imipramine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Imipramine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Imipramine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Imipramine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Imipramine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Imipramine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Imipramine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Imipramine.Approved
CandesartanThe serum concentration of Imipramine can be increased when it is combined with Candesartan.Approved
CandoxatrilThe serum concentration of Imipramine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Imipramine can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Imipramine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Imipramine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Imipramine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Imipramine.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Imipramine.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Imipramine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Imipramine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Imipramine.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Imipramine.Approved
CarvedilolThe serum concentration of Imipramine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Imipramine can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Imipramine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Imipramine is combined with Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Imipramine.Approved, Vet Approved
CeritinibThe serum concentration of Imipramine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Imipramine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Imipramine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Imipramine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Imipramine.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Imipramine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Imipramine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Imipramine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Imipramine.Approved
ChloroquineImipramine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Imipramine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Imipramine.Approved
ChlorphentermineImipramine may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineImipramine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Imipramine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Imipramine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Imipramine.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Imipramine.Approved
CholecalciferolThe metabolism of Imipramine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Imipramine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Imipramine can be decreased when it is combined with Cholic Acid.Approved
ChymostatinThe serum concentration of Imipramine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Imipramine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Imipramine can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Imipramine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Imipramine.Approved
CimetidineThe metabolism of Imipramine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Imipramine can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Imipramine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Imipramine.Approved
CiprofloxacinImipramine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineImipramine may increase the vasopressor activities of Cirazoline.Experimental
CisaprideImipramine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Imipramine.Approved
CitalopramThe risk or severity of adverse effects can be increased when Imipramine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Imipramine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Imipramine can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Clenbuterol.Approved, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Imipramine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Imipramine is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Imipramine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Imipramine.Approved, Investigational
ClofazimineThe serum concentration of Imipramine can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Imipramine.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Imipramine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Imipramine is combined with Clonazepam.Approved, Illicit
ClonidineImipramine may decrease the antihypertensive activities of Clonidine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Imipramine.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Imipramine.Approved, Illicit
ClotrimazoleThe metabolism of Imipramine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineImipramine may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Imipramine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Imipramine.Approved
CocaineThe metabolism of Imipramine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Imipramine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Imipramine.Approved
ColforsinThe serum concentration of Imipramine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Imipramine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Imipramine.Approved
CrizotinibImipramine may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Imipramine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Imipramine is combined with Cyclobenzaprine.Approved
CyclophosphamideThe serum concentration of Imipramine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Imipramine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Imipramine.Approved
Cyproterone acetateThe serum concentration of Imipramine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Imipramine.Approved
DabrafenibThe serum concentration of Imipramine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Imipramine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Imipramine can be increased when it is combined with Dactinomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Imipramine is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Imipramine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Imipramine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Imipramine.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Imipramine.Approved, Investigational
DarunavirThe serum concentration of Imipramine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Imipramine.Approved
DasatinibThe serum concentration of Imipramine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Imipramine can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Imipramine.Approved
DeferasiroxThe serum concentration of Imipramine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Imipramine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Imipramine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Imipramine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desipramine.Approved
DesloratadineThe serum concentration of Imipramine can be increased when it is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Imipramine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Imipramine.Vet Approved
DexamethasoneThe serum concentration of Imipramine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Imipramine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Imipramine.Approved, Illicit, Withdrawn
DexmedetomidineImipramine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Imipramine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Imipramine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Imipramine is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Imipramine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Imipramine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Imipramine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Imipramine.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Imipramine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Imipramine.Approved
DicoumarolImipramine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionImipramine may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Imipramine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Imipramine is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Imipramine.Approved
DigoxinThe serum concentration of Imipramine can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Imipramine.Approved, Illicit
DihydroergotamineImipramine may decrease the antihypertensive activities of Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Imipramine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Imipramine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Imipramine.Illicit
DiltiazemThe metabolism of Imipramine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Imipramine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Imipramine.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Imipramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Imipramine.Approved, Illicit
DipivefrinImipramine may decrease the antihypertensive activities of Dipivefrin.Approved
DipyridamoleThe serum concentration of Imipramine can be increased when it is combined with Dipyridamole.Approved
DisopyramideImipramine may increase the QTc-prolonging activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Imipramine.Approved, Investigational
DofetilideImipramine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronImipramine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneImipramine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Imipramine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Imipramine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Imipramine.Vet Approved
DoxazosinThe serum concentration of Imipramine can be increased when it is combined with Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Imipramine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Imipramine.Approved, Investigational
DoxorubicinThe serum concentration of Imipramine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Imipramine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Imipramine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved, Illicit
DronedaroneImipramine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Imipramine.Experimental, Illicit
DroxidopaImipramine may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Imipramine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Imipramine.Approved
EcabetThe serum concentration of Imipramine can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Imipramine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Imipramine.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Imipramine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Imipramine.Approved
EfavirenzThe serum concentration of Imipramine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Imipramine.Approved
ElafinThe serum concentration of Imipramine can be increased when it is combined with Elafin.Investigational
ElbasvirThe serum concentration of Imipramine can be increased when it is combined with Elbasvir.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Imipramine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Imipramine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Imipramine.Approved
EnalaprilThe serum concentration of Imipramine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Imipramine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Imipramine can be increased when it is combined with Enalkiren.Experimental
EncainideThe metabolism of Encainide can be decreased when combined with Imipramine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Imipramine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Imipramine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Imipramine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Imipramine can be decreased when it is combined with Enzalutamide.Approved
EphedraImipramine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Imipramine.Approved, Investigational
EpinephrineImipramine may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Imipramine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Imipramine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Imipramine.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Imipramine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ergonovine.Approved
ErgotamineImipramine may decrease the antihypertensive activities of Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Imipramine.Approved, Investigational
ErythromycinImipramine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Imipramine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Imipramine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Imipramine.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Imipramine.Approved
EsomeprazoleThe metabolism of Imipramine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Imipramine.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Imipramine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Imipramine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Imipramine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Imipramine can be decreased when it is combined with Estrone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Imipramine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Imipramine.Approved
EthanolImipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Imipramine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Imipramine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Imipramine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Imipramine is combined with Ethotoin.Approved
Ethyl biscoumacetateImipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Imipramine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Imipramine.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Imipramine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Imipramine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Imipramine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Imipramine.Approved
EtomidateImipramine may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Etoperidone.Approved
EtoposideThe serum concentration of Imipramine can be increased when it is combined with Etoposide.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Imipramine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Imipramine.Illicit, Vet Approved
EtravirineThe serum concentration of Imipramine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Imipramine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Imipramine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Imipramine is combined with Felbamate.Approved
FelodipineThe serum concentration of Imipramine can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Imipramine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Imipramine.Approved
FenoterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Imipramine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Imipramine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Imipramine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Imipramine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Imipramine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Imipramine.Approved, Investigational
FlecainideImipramine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Imipramine is combined with Flibanserin.Approved
FluconazoleThe metabolism of Imipramine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Imipramine.Approved, Illicit
FluindioneImipramine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Imipramine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Imipramine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Imipramine.Approved, Vet Approved
FlupentixolImipramine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Imipramine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Imipramine can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Imipramine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Imipramine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Imipramine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Imipramine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Imipramine.Approved, Investigational
FosamprenavirThe serum concentration of Imipramine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Imipramine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Imipramine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Imipramine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Imipramine.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Imipramine is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Imipramine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Imipramine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Imipramine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Imipramine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Imipramine is combined with gabapentin enacarbil.Approved
GabexateThe serum concentration of Imipramine can be increased when it is combined with Gabexate.Investigational
Gadobenic acidImipramine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Imipramine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Imipramine.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Imipramine.Approved, Investigational
GeldanamycinThe serum concentration of Imipramine can be increased when it is combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Imipramine.Approved
GemfibrozilThe metabolism of Imipramine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinImipramine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Imipramine can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Imipramine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Imipramine.Approved, Illicit
GlyburideThe serum concentration of Imipramine can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Imipramine can be increased when it is combined with Glycerol.Experimental
GM6001The serum concentration of Imipramine can be increased when it is combined with GM6001.Experimental
GoserelinImipramine may increase the QTc-prolonging activities of Goserelin.Approved
Gramicidin DThe serum concentration of Imipramine can be increased when it is combined with Gramicidin D.Approved
GranisetronImipramine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Imipramine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Imipramine.Withdrawn
GuanabenzImipramine may decrease the antihypertensive activities of Guanabenz.Approved
GuanfacineImipramine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Imipramine.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Imipramine.Approved
HaloperidolImipramine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Imipramine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Imipramine.Approved, Illicit
HexobarbitalThe metabolism of Imipramine can be increased when combined with Hexobarbital.Approved
HirulogThe serum concentration of Imipramine can be increased when it is combined with Hirulog.Experimental
HydracarbazineHydracarbazine may increase the serotonergic activities of Imipramine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Imipramine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Imipramine.Approved, Vet Approved
HydrocodoneImipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Imipramine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Imipramine.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Imipramine.Approved, Illicit
Hydroxyamphetamine hydrobromideImipramine may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Imipramine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Imipramine.Approved
IbutilideImipramine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Imipramine.Approved
IdelalisibThe serum concentration of Imipramine can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Imipramine can be increased when it is combined with idraparinux.Investigational
IloperidoneImipramine may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Imipramine.Approved, Investigational
ImatinibThe metabolism of Imipramine can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Imipramine can be increased when it is combined with Imidapril.Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Imipramine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Imipramine.Approved
IndinavirThe metabolism of Imipramine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Imipramine can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Imipramine is combined with Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Imipramine.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Imipramine.Approved
IproclozideIproclozide may increase the serotonergic activities of Imipramine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Imipramine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Imipramine.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Imipramine.Approved, Investigational
IsavuconazoniumThe metabolism of Imipramine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Imipramine.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Imipramine is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Imipramine.Approved, Vet Approved
IsoflurophateThe serum concentration of Imipramine can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Imipramine can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Imipramine is combined with Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Imipramine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Imipramine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Imipramine.Approved, Withdrawn
IsradipineThe metabolism of Imipramine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Imipramine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Imipramine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Imipramine.Approved, Vet Approved
IxazomibThe serum concentration of Imipramine can be increased when it is combined with Ixazomib.Approved
KetamineThe serum concentration of Imipramine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Imipramine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Imipramine.Approved
KetoconazoleThe metabolism of Imipramine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Imipramine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Imipramine is combined with Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Imipramine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Imipramine.Approved, Investigational
LansoprazoleThe serum concentration of Imipramine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Imipramine can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Imipramine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Imipramine.Approved
LenvatinibImipramine may increase the QTc-prolonging activities of Lenvatinib.Approved
LepirudinThe serum concentration of Imipramine can be increased when it is combined with Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Imipramine is combined with Lercanidipine.Approved, Investigational
LeuprolideImipramine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Imipramine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Imipramine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Imipramine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Imipramine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Imipramine is combined with Levocetirizine.Approved
LevodopaImipramine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinImipramine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Imipramine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Imipramine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Imipramine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Imipramine is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Imipramine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Imipramine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Imipramine can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Imipramine.Approved, Investigational
LiothyronineThe serum concentration of Imipramine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Imipramine can be decreased when it is combined with Liotrix.Approved
LisdexamfetamineImipramine may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Imipramine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Imipramine.Approved
LithiumLithium may increase the neurotoxic activities of Imipramine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Imipramine.Illicit
LofexidineImipramine may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Imipramine can be increased when it is combined with Lomitapide.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Imipramine.Approved
LoperamideThe serum concentration of Imipramine can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Imipramine can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Imipramine can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Imipramine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Imipramine is combined with Lorcaserin.Approved
LosartanThe serum concentration of Imipramine can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Imipramine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Imipramine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Imipramine.Investigational
LuliconazoleThe serum concentration of Imipramine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Imipramine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineImipramine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Imipramine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Imipramine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Imipramine is combined with Maprotiline.Approved
MebanazineMebanazine may increase the serotonergic activities of Imipramine.Withdrawn
MebendazoleThe serum concentration of Imipramine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Imipramine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Imipramine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Imipramine.Vet Approved
MefloquineThe serum concentration of Imipramine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Imipramine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Imipramine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Imipramine.Approved
MephedroneImipramine may increase the stimulatory activities of Mephedrone.Investigational
MephentermineImipramine may increase the vasopressor activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Imipramine.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Imipramine.Approved, Vet Approved
MeprobamateThe serum concentration of Imipramine can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineThe metabolism of Mequitazine can be decreased when combined with Imipramine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Imipramine.Approved
MetaraminolImipramine may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Imipramine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Imipramine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Imipramine.Approved, Illicit
MethamphetamineImipramine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Imipramine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Imipramine.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Imipramine.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Imipramine.Approved, Vet Approved
MethohexitalThe metabolism of Imipramine can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Imipramine.Approved
MethotrimeprazineImipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineImipramine may increase the vasopressor activities of Methoxamine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Imipramine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Imipramine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Imipramine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Imipramine.Approved
Methylene blueImipramine may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Imipramine.Approved, Investigational
MethylphenobarbitalThe metabolism of Imipramine can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Imipramine.Approved, Vet Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Imipramine.Approved, Illicit, Withdrawn
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Imipramine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Imipramine.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Imipramine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Imipramine.Approved, Investigational
MetyrosineImipramine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Imipramine can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Imipramine.Approved
MibefradilThe serum concentration of Imipramine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Imipramine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Imipramine can be decreased when it is combined with Midazolam.Approved, Illicit
MidodrineImipramine may increase the vasopressor activities of Midodrine.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Imipramine.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Imipramine is combined with Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Imipramine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Imipramine.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Imipramine.Approved
MirtazapineImipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitomycinThe serum concentration of Imipramine can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Imipramine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Imipramine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MMDAImipramine may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Imipramine.Approved
ModafinilThe serum concentration of Imipramine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Imipramine can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Imipramine.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Imipramine.Approved, Investigational
MoxifloxacinImipramine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Imipramine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Imipramine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Imipramine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Imipramine.Approved
NafamostatThe serum concentration of Imipramine can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Imipramine can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Imipramine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Imipramine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Imipramine.Approved, Vet Approved
NaltrexoneThe serum concentration of Imipramine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaphazolineImipramine may decrease the antihypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Imipramine is combined with Naratriptan.Approved, Investigational
NaringeninThe serum concentration of Imipramine can be increased when it is combined with Naringenin.Experimental
NateglinideThe metabolism of Nateglinide can be decreased when combined with Imipramine.Approved, Investigational
NCX 4016The serum concentration of Imipramine can be increased when it is combined with NCX 4016.Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Imipramine.Approved, Investigational
NefazodoneThe metabolism of Imipramine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Imipramine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Imipramine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Imipramine.Approved, Investigational
NetupitantThe serum concentration of Imipramine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Imipramine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Imipramine.Withdrawn
NicardipineThe serum concentration of Imipramine can be increased when it is combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Imipramine.Approved
NicorandilImipramine may increase the hypotensive activities of Nicorandil.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Imipramine.Approved
NifedipineThe serum concentration of Imipramine can be decreased when it is combined with Nifedipine.Approved
NilotinibImipramine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Imipramine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Imipramine.Approved
NisoldipineThe serum concentration of Imipramine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Imipramine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Imipramine can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Imipramine is combined with Nitric Oxide.Approved
NitroaspirinThe serum concentration of Imipramine can be increased when it is combined with Nitroaspirin.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Imipramine.Approved, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Imipramine.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Imipramine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Imipramine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Imipramine.Approved
NorepinephrineImipramine may decrease the antihypertensive activities of Norepinephrine.Approved
NorethisteroneThe serum concentration of Imipramine can be decreased when it is combined with Norethisterone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Imipramine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Imipramine is combined with Obinutuzumab.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Imipramine.Withdrawn
OfloxacinImipramine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Imipramine.Approved, Investigational
OlaparibThe metabolism of Imipramine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Imipramine.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Imipramine is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Imipramine can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Imipramine.Approved
OmeprazoleThe serum concentration of Imipramine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronImipramine may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Imipramine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Imipramine is combined with Orciprenaline.Approved
OrphenadrineImipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Imipramine.Investigational
OsimertinibThe serum concentration of Imipramine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Imipramine can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Imipramine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Imipramine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Imipramine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Imipramine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Imipramine.Approved, Illicit, Investigational
OxymetazolineImipramine may decrease the antihypertensive activities of Oxymetazoline.Approved
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Imipramine.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Imipramine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Imipramine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Imipramine can be increased when it is combined with Palbociclib.Approved
PaliperidoneImipramine may decrease the antihypertensive activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Imipramine can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronPalonosetron may increase the serotonergic activities of Imipramine.Approved, Investigational
PanobinostatThe serum concentration of Imipramine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Imipramine can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Imipramine.Approved
ParaldehydeImipramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylinePargyline may increase the serotonergic activities of Imipramine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Imipramine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Imipramine.Approved
Peginterferon alfa-2bThe serum concentration of Imipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Imipramine.Approved, Investigational
PentamidineImipramine may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Imipramine.Approved, Vet Approved
PentobarbitalThe metabolism of Imipramine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
PerazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Perazine.Investigational
PerflutrenImipramine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideImipramine may decrease the antihypertensive activities of Pergolide.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Imipramine.Approved
PerindoprilThe serum concentration of Imipramine can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Imipramine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Imipramine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Imipramine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Imipramine.Withdrawn
PhenelzinePhenelzine may increase the serotonergic activities of Imipramine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Imipramine.Approved, Withdrawn
PhenindioneImipramine may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Imipramine.Withdrawn
PhenobarbitalThe metabolism of Imipramine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Imipramine.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Imipramine.Withdrawn
PhenprocoumonImipramine may increase the anticoagulant activities of Phenprocoumon.Approved
PhentermineImipramine may increase the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Phentolamine.Approved
PhenylephrineImipramine may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineImipramine may decrease the antihypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Imipramine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Imipramine can be increased when it is combined with Phosphoramidon.Experimental
PimozideImipramine may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Imipramine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Imipramine.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Imipramine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Imipramine.Approved
PirbuterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Imipramine is combined with Piritramide.Investigational
PirlindolePirlindole may increase the serotonergic activities of Imipramine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Imipramine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Imipramine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Imipramine is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Imipramine can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Imipramine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Imipramine.Approved
PosaconazoleThe metabolism of Imipramine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleImipramine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Imipramine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Imipramine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Imipramine.Approved, Illicit
PrazosinThe serum concentration of Imipramine can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Imipramine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Imipramine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Imipramine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Imipramine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Imipramine.Approved
PrimaquineImipramine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Imipramine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Imipramine can be increased when it is combined with Prinomastat.Investigational
ProbenecidThe serum concentration of Imipramine can be increased when it is combined with Probenecid.Approved
ProcainamideImipramine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Imipramine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Procaterol.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Imipramine.Approved, Vet Approved
ProgesteroneThe serum concentration of Imipramine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineImipramine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Promethazine.Approved
PropafenoneThe serum concentration of Imipramine can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Imipramine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Propericiazine.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Imipramine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Imipramine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Imipramine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Imipramine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Imipramine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Imipramine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Imipramine.Investigational
PseudoephedrineImipramine may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuazepamThe serum concentration of Imipramine can be increased when it is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Imipramine can be increased when it is combined with Quercetin.Experimental
QuetiapineImipramine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Imipramine can be increased when it is combined with Quinacrine.Approved
QuinaprilThe serum concentration of Imipramine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineImipramine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineImipramine may increase the QTc-prolonging activities of Quinine.Approved
RacecadotrilThe serum concentration of Imipramine can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Imipramine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Imipramine is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Imipramine can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Imipramine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Imipramine.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Imipramine.Approved
ReboxetineThe serum concentration of Imipramine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Imipramine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Imipramine.Approved
RemikirenThe serum concentration of Imipramine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Imipramine.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Imipramine.Investigational
ReserpineThe serum concentration of Imipramine can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Imipramine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Imipramine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Imipramine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Imipramine.Approved, Investigational
RilpivirineThe serum concentration of Imipramine can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Imipramine.Approved
RisperidoneImipramine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Imipramine is combined with Ritanserin.Investigational
RitobegronImipramine may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ritodrine.Approved
RitonavirThe metabolism of Imipramine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Imipramine can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Imipramine is combined with Rizatriptan.Approved
RolapitantThe serum concentration of Imipramine can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Imipramine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Imipramine.Vet Approved
RopiniroleImipramine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Imipramine.Approved
RotigotineImipramine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Imipramine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Imipramine.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Imipramine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the serotonergic activities of Imipramine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Imipramine is combined with Sage 547.Investigational
SalbutamolThe risk or severity of adverse effects can be increased when Imipramine is combined with Salbutamol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Imipramine.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Salmeterol.Approved
SaquinavirThe metabolism of Imipramine can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Imipramine can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe serum concentration of Imipramine can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Imipramine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Imipramine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Imipramine.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Imipramine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Imipramine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Imipramine.Approved, Vet Approved
SildenafilThe metabolism of Imipramine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Imipramine.Approved
SiltuximabThe serum concentration of Imipramine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Imipramine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Imipramine can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Imipramine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Imipramine can be increased when it is combined with Sitagliptin.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Imipramine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Imipramine.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Imipramine.Approved, Investigational
SotalolImipramine may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Imipramine.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Imipramine.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Imipramine.Experimental
SpiraprilThe serum concentration of Imipramine can be increased when it is combined with Spirapril.Approved
SpironolactoneThe serum concentration of Imipramine can be increased when it is combined with Spironolactone.Approved
St. John's WortThe metabolism of Imipramine can be increased when combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Imipramine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Imipramine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Imipramine is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Imipramine can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Imipramine.Approved, Investigational
SulfinpyrazoneThe serum concentration of Imipramine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleImipramine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Imipramine.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Imipramine is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Imipramine can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantImipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Imipramine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Imipramine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Imipramine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Imipramine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Imipramine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Imipramine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Imipramine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Imipramine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Imipramine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Imipramine.Investigational, Withdrawn
TelaprevirThe metabolism of Imipramine can be decreased when combined with Telaprevir.Approved
TelavancinImipramine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Imipramine can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Imipramine can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Imipramine.Approved
TemocaprilThe serum concentration of Imipramine can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Imipramine.Approved
TenofovirThe metabolism of Imipramine can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Imipramine can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Imipramine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Imipramine is combined with Terbutaline.Approved
TerfenadineThe serum concentration of Imipramine can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Imipramine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Imipramine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Imipramine can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineImipramine may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Imipramine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Imipramine.Investigational
ThalidomideImipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Imipramine can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Imipramine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Imipramine can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Imipramine.Approved
ThiorphanThe serum concentration of Imipramine can be increased when it is combined with Thiorphan.Experimental
ThiotepaThe metabolism of Imipramine can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Imipramine.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Imipramine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Imipramine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Imipramine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Imipramine.Approved
TiclopidineThe metabolism of Imipramine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Imipramine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Imipramine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Imipramine.Approved
TipranavirThe metabolism of Imipramine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Imipramine.Approved
TocilizumabThe serum concentration of Imipramine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Imipramine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Imipramine.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Imipramine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Imipramine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Imipramine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Imipramine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Imipramine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Imipramine.Approved
ToremifeneImipramine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Imipramine.Approved, Investigational
TramadolImipramine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Imipramine can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Imipramine.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Imipramine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Imipramine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Imipramine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Imipramine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Imipramine.Approved
TrifluoperazineThe serum concentration of Imipramine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Imipramine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Imipramine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Imipramine.Approved
TroleandomycinThe serum concentration of Imipramine can be increased when it is combined with Troleandomycin.Approved
TropisetronTropisetron may increase the serotonergic activities of Imipramine.Investigational
UbenimexThe serum concentration of Imipramine can be increased when it is combined with Ubenimex.Experimental
Uc1010The risk or severity of adverse effects can be increased when Imipramine is combined with Uc1010.Investigational
UlinastatinThe serum concentration of Imipramine can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Imipramine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Imipramine.Approved
Valproic AcidThe serum concentration of Imipramine can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Imipramine.Approved, Investigational
VandetanibImipramine may increase the QTc-prolonging activities of Vandetanib.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Imipramine.Approved
VemurafenibThe serum concentration of Imipramine can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Imipramine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Imipramine.Approved
VerapamilThe metabolism of Imipramine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Imipramine is combined with Vigabatrin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Vilazodone.Approved
VildagliptinThe serum concentration of Imipramine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Imipramine can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Imipramine.Approved, Investigational
VincristineThe serum concentration of Imipramine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Imipramine can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Imipramine.Approved
VoriconazoleThe metabolism of Imipramine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Imipramine is combined with Vortioxetine.Approved
WarfarinImipramine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Imipramine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Imipramine.Vet Approved
XylometazolineImipramine may decrease the antihypertensive activities of Xylometazoline.Approved
Ym150The serum concentration of Imipramine can be increased when it is combined with Ym150.Investigational
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Imipramine.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Imipramine.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Imipramine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Imipramine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Imipramine.Approved
ZimelidineThe serum concentration of Imipramine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneImipramine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Imipramine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Imipramine.Approved, Investigational
ZolpidemImipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Imipramine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Imipramine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Imipramine.Approved
ZuclopenthixolImipramine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid St.John's Wort.
  • Do not take fibers at the same time.
  • Take with food.
References
Synthesis Reference

U.S. Patent 2,554,736.

General ReferencesNot Available
External Links
ATC CodesN06AA02
AHFS Codes
  • 28:16.04.28
PDB EntriesNot Available
FDA labelDownload (152 KB)
MSDSDownload (73.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9822
Blood Brain Barrier+0.9865
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7684
P-glycoprotein inhibitor IInhibitor0.8662
P-glycoprotein inhibitor IIInhibitor0.6205
Renal organic cation transporterInhibitor0.8541
CYP450 2C9 substrateNon-substrate0.7799
CYP450 2D6 substrateSubstrate0.9532
CYP450 3A4 substrateSubstrate0.6718
CYP450 1A2 substrateNon-inhibitor0.7583
CYP450 2C9 inhibitorNon-inhibitor0.9089
CYP450 2D6 inhibitorInhibitor0.9017
CYP450 2C19 inhibitorNon-inhibitor0.9304
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8399
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9329
BiodegradationNot ready biodegradable0.9819
Rat acute toxicity3.0187 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9172
hERG inhibition (predictor II)Inhibitor0.7771
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
  • Actavis totowa llc
  • Lederle laboratories div american cyanamid co
  • Lupin ltd
  • Mutual pharmaceutical co inc
  • Par pharmaceutical inc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Abbott laboratories pharmaceutical products div
  • Alra laboratories inc
  • Sanofi aventis us llc
  • Tyco healthcare group lp
  • Odyssey pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
TabletOral75 mg
TabletOral10 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
TabletOral10 mg
TabletOral25 mg
TabletOral50 mg
Tablet, sugar coatedOral10 mg/1
Tablet, sugar coatedOral25 mg/1
Tablet, sugar coatedOral50 mg/1
CapsuleOral100 mg/1
CapsuleOral125 mg/1
CapsuleOral150 mg/1
CapsuleOral75 mg/1
Prices
Unit descriptionCostUnit
Tofranil-PM 30 125 mg capsule Bottle588.33USD bottle
Tofranil-PM 30 150 mg capsule Bottle588.33USD bottle
Tofranil-PM 30 75 mg capsule Bottle588.33USD bottle
Tofranil 30 50 mg tablet Bottle185.09USD bottle
Trimipramine maleate powder51.0USD g
Tofranil-pm 100 mg capsule19.23USD capsule
Tofranil-pm 150 mg capsule18.86USD capsule
Tofranil-pm 75 mg capsule18.86USD capsule
Tofranil-pm 125 mg capsule18.68USD capsule
Imipramine pamoate 75 mg capsule16.35USD capsule
Imipramine pamoate 100 mg capsule15.17USD capsule
Imipramine pamoate 125 mg capsule15.17USD capsule
Imipramine pamoate 150 mg capsule15.17USD capsule
Tofranil 50 mg tablet6.64USD tablet
Surmontil 100 mg capsule5.92USD capsule
Tofranil 25 mg tablet4.97USD tablet
Tofranil 10 mg tablet4.73USD tablet
Surmontil 50 mg capsule4.07USD capsule
Trimipramine Maleate 50 mg capsule3.27USD capsule
Trimipramine 50 mg capsule3.14USD capsule
Surmontil 25 mg capsule2.49USD capsule
Cenestin 0.3 mg tablet2.21USD tablet
Cenestin 0.45 mg tablet2.21USD tablet
Cenestin 0.625 mg tablet2.21USD tablet
Cenestin 0.9 mg tablet2.21USD tablet
Cenestin 1.25 mg tablet2.21USD tablet
Trimipramine 25 mg capsule1.92USD capsule
Apo-Trimip 100 mg Tablet0.97USD tablet
Imipramine hcl powder0.77USD g
Apo-Trimip 75 mg Capsule0.77USD capsule
Apo-Imipramine 75 mg Tablet0.58USD tablet
Tofranil 50 mg Tablet0.57USD tablet
Apo-Trimip 50 mg Tablet0.57USD tablet
Imipramine hcl 10 mg tablet0.46USD tablet
Imipramine hcl 50 mg tablet0.44USD tablet
Apo-Imipramine 50 mg Tablet0.4USD tablet
Imipramine hcl 25 mg tablet0.35USD tablet
Apo-Trimip 25 mg Tablet0.29USD tablet
Apo-Imipramine 25 mg Tablet0.25USD tablet
Apo-Trimip 12.5 mg Tablet0.23USD tablet
Apo-Imipramine 10 mg Tablet0.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point174-175U.S. Patent 2,554,736.
boiling point160 °C at 1.00E-01 mm HgPhysProp
water solubility18.2 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.80HANSCH,C ET AL. (1995)
logS-4.19ADME Research, USCD
Caco2 permeability-4.85ADME Research, USCD
pKa9.4SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0664 mg/mLALOGPS
logP4.53ALOGPS
logP4.28ChemAxon
logS-3.6ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity90.61 m3·mol-1ChemAxon
Polarizability33.39 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.2 KB)
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-000i-9000000000-55d924fd00e5b357ce9eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-000i-9000000000-eb3c0ecdffc5d9d95e33View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-0ab9-9432000000-033c51459b692622ee7dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (Unknown) , Positivesplash10-0019-7490000000-bb99ef31a755d9f6ba14View in MoNA
MSMass Spectrum (Electron Ionization)splash10-0543-8890000000-6cf8e84f007ce7c750f2View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassDibenzazepines
Direct ParentDibenzazepines
Alternative Parents
Substituents
  • Dibenzazepine
  • Alkyldiarylamine
  • Azepine
  • Benzenoid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Mitchell HA, Ahern TH, Liles LC, Javors MA, Weinshenker D: The effects of norepinephrine transporter inactivation on locomotor activity in mice. Biol Psychiatry. 2006 Nov 15;60(10):1046-52. Epub 2006 Aug 7. [PubMed:16893531 ]
  2. Dziedzicka-Wasylewska M, Faron-Gorecka A, Kusmider M, Drozdowska E, Rogoz Z, Siwanowicz J, Caron MG, Bonisch H: Effect of antidepressant drugs in mice lacking the norepinephrine transporter. Neuropsychopharmacology. 2006 Nov;31(11):2424-32. Epub 2006 Mar 22. [PubMed:16554743 ]
  3. Anton M, Wagner B, Haubner R, Bodenstein C, Essien BE, Bonisch H, Schwaiger M, Gansbacher B, Weber WA: Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells. J Gene Med. 2004 Jan;6(1):119-26. [PubMed:14716684 ]
  4. Kantor L, Hewlett GH, Park YH, Richardson-Burns SM, Mellon MJ, Gnegy ME: Protein kinase C and intracellular calcium are required for amphetamine-mediated dopamine release via the norepinephrine transporter in undifferentiated PC12 cells. J Pharmacol Exp Ther. 2001 Jun;297(3):1016-24. [PubMed:11356924 ]
  5. Tatsumi M, Jansen K, Blakely RD, Richelson E: Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999 Mar 5;368(2-3):277-83. [PubMed:10193665 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Leboyer M, Quintin P, Manivet P, Varoquaux O, Allilaire JF, Launay JM: Decreased serotonin transporter binding in unaffected relatives of manic depressive patients. Biol Psychiatry. 1999 Dec 15;46(12):1703-6. [PubMed:10624553 ]
  2. Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH: Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther. 2000 Jun;293(3):870-8. [PubMed:10869387 ]
  3. Quintin P, Benkelfat C, Launay JM, Arnulf I, Pointereau-Bellenger A, Barbault S, Alvarez JC, Varoquaux O, Perez-Diaz F, Jouvent R, Leboyer M: Clinical and neurochemical effect of acute tryptophan depletion in unaffected relatives of patients with bipolar affective disorder. Biol Psychiatry. 2001 Aug 1;50(3):184-90. [PubMed:11513817 ]
  4. Goulet M, Miller GM, Bendor J, Liu S, Meltzer PC, Madras BK: Non-amines, drugs without an amine nitrogen, potently block serotonin transport: novel antidepressant candidates? Synapse. 2001 Dec 1;42(3):129-40. [PubMed:11746710 ]
  5. Barkan T, Gurwitz D, Levy G, Weizman A, Rehavi M: Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes. Eur Neuropsychopharmacol. 2004 May;14(3):237-43. [PubMed:15056483 ]
  6. Schloss P, Betz H: Heterogeneity of antidepressant binding sites on the recombinant rat serotonin transporter SERT1. Biochemistry. 1995 Oct 3;34(39):12590-5. [PubMed:7548008 ]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Zanoveli JM, Nogueira RL, Zangrossi H Jr: Chronic imipramine treatment sensitizes 5-HT1A and 5-HT 2 A receptors in the dorsal periaqueductal gray matter: evidence from the elevated T-maze test of anxiety. Behav Pharmacol. 2005 Nov;16(7):543-52. [PubMed:16170231 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Mediates the major part of the dendritic A-type current I(SA) in brain neurons (By similarity). This current is activated at membrane potentials that are below the threshold for action potentials. It regulates neuronal excitability, prolongs the latency before the firs...
Gene Name:
KCND2
Uniprot ID:
Q9NZV8
Molecular Weight:
70535.825 Da
References
  1. Casis O, Sanchez-Chapula JA: Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol. 1998 Oct;32(4):521-6. [PubMed:9781919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels. May contribute to I(To) current in heart and I(Sa) current in neurons. Channel properties are modulated by interactions with other alpha subunits and with regulatory subunits.
Gene Name:
KCND3
Uniprot ID:
Q9UK17
Molecular Weight:
73450.53 Da
References
  1. Casis O, Sanchez-Chapula JA: Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol. 1998 Oct;32(4):521-6. [PubMed:9781919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistbinder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J: Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl). 1996 Aug;126(3):234-40. [PubMed:8876023 ]
  2. Roth BL: Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry. 1994 Jun;6(2):67-78. [PubMed:7804391 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Lucchelli A, Santagostino-Barbone MG, D'Agostino G, Masoero E, Tonini M: The interaction of antidepressant drugs with enteric 5-HT7 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):284-9. [PubMed:10997731 ]
  2. Roth BL: Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry. 1994 Jun;6(2):67-78. [PubMed:7804391 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS: Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr. 1998 Mar;178:440-66. [PubMed:9686407 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Peddi S, Roth BL, Glennon RA, Westkaemper RB: Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA). Bioorg Med Chem Lett. 2004 May 3;14(9):2279-83. [PubMed:15081025 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Teschemacher AG, Seward EP, Hancox JC, Witchel HJ: Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol. 1999 Sep;128(2):479-85. [PubMed:10510461 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Melikian HE, Buckley KM: Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci. 1999 Sep 15;19(18):7699-710. [PubMed:10479674 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
activator
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Haddjeri N, Blier P, de Montigny C: Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci. 1998 Dec 1;18(23):10150-6. [PubMed:9822768 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Grimaldi B, Bonnin A, Fillion MP, Ruat M, Traiffort E, Fillion G: Characterization of 5-ht6 receptor and expression of 5-ht6 mRNA in the rat brain during ontogenetic development. Naunyn Schmiedebergs Arch Pharmacol. 1998 Apr;357(4):393-400. [PubMed:9606024 ]
  2. Roth BL: Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry. 1994 Jun;6(2):67-78. [PubMed:7804391 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Koyama E, Chiba K, Tani M, Ishizaki T: Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210. [PubMed:9190854 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Shin JG, Park JY, Kim MJ, Shon JH, Yoon YR, Cha IJ, Lee SS, Oh SW, Kim SW, Flockhart DA: Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos. 2002 Oct;30(10):1102-7. [PubMed:12228186 ]
  2. Morinobu S, Tanaka T, Kawakatsu S, Totsuka S, Koyama E, Chiba K, Ishizaki T, Kubota T: Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry Clin Neurosci. 1997 Aug;51(4):253-7. [PubMed:9316174 ]
  3. Madsen H, Rasmussen BB, Brosen K: Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. Clin Pharmacol Ther. 1997 Mar;61(3):319-24. [PubMed:9084457 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Koyama E, Chiba K, Tani M, Ishizaki T: Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210. [PubMed:9190854 ]
  6. Obach RS, Reed-Hagen AE: Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos. 2002 Jul;30(7):831-7. [PubMed:12065442 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Brosen K: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet. 1995;29 Suppl 1:20-5. [PubMed:8846619 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Koyama E, Chiba K, Tani M, Ishizaki T: Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210. [PubMed:9190854 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Koyama E, Chiba K, Tani M, Ishizaki T: Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210. [PubMed:9190854 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  3. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365 ]
  2. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. [PubMed:10966924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. [PubMed:10825452 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11